Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Depression in Parkinson's Disease
NCT00304161Phase 4Completed
- Sponsor
- University of Pennsylvania
- Start
- Jul 2004
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Atomoxetine with Placebo (2 arms). Primary endpoint: Inventory of Depressive Symptomatology-Clinician Rated at 8 weeks. Started Jul 2004; status: completed.
02
Drugs
atomoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00304161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304161.